Melia W M, Johnson P J, Williams R
Liver Unit, King's College Hospital, London, England.
Cancer Treat Rep. 1987 Dec;71(12):1213-6.
Following reports that specific estrogen receptors could be detected in samples of hepatocellular carcinoma tissue, a prospective randomized controlled trial was undertaken in 59 patients, half of whom received doxorubicin (60 mg/m2 at 3-week intervals) and half doxorubicin and tamoxifen (10 mg twice per day). Response occurred in three (11%) of those patients receiving doxorubicin alone and in four (16%) of those given both drugs. This difference was not statistically significant nor was the difference in survival when compared by life-table analysis. One patient treated with both drugs achieved complete remission for 30 months which was maintained (on tamoxifen alone) for 18 months before death from a non-tumor-related condition. Tamoxifen may have a role in maintenance of doxorubicin-induced remissions.
有报道称在肝细胞癌组织样本中可检测到特定的雌激素受体，随后对59例患者进行了一项前瞻性随机对照试验，其中一半患者接受阿霉素治疗（每3周60mg/m²），另一半患者接受阿霉素和他莫昔芬联合治疗（他莫昔芬每日两次，每次10mg）。单独接受阿霉素治疗的患者中有3例（11%）出现反应，接受两种药物治疗的患者中有4例（16%）出现反应。通过生命表分析比较，这种差异无统计学意义，生存率差异也无统计学意义。一名接受两种药物治疗的患者实现了30个月的完全缓解，在因非肿瘤相关疾病死亡前（仅使用他莫昔芬）维持缓解18个月。他莫昔芬可能在维持阿霉素诱导的缓解中发挥作用。
